Table 2 Clinical outcomes comparison.
Outcomes | Pre-post treatment difference (mean, SD) | linear regression (OW cohort) | Sensitivity analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|
Model 1 a | Model 2 b | Model 3 c | |||||||
β(95%CI) | P value | β(95%CI) | P value | β(95%CI) | P value | β(95%CI) | P value | ||
ICIQ-UI SF | |||||||||
EPNS | 9.26 (5.19) | 0.00 (Reference) | 0.00 (Reference) | 0.00 (Reference) | 0.00 (Reference) | ||||
PFMT + TES | 2.43 (5.99) | -4.34 (-6.65 to -2.02) | < 0.001 | -6.83 (-8.21 to -5.45) | < 0.001 | -4.39 (-6.54 to -2.23) | < 0.001 | -3.94 (-6.25 to -1.64) | < 0.001 |
24-hr pad test urine loss, g | |||||||||
EPNS | 639.22 (383.99) | 0.00 (Reference) | 0.00 (Reference) | 0.00 (Reference) | 0.00 (Reference) | ||||
PMFT + TES | 109.17 (331.60) | -631.26 (-750.81 to -511.70) | < 0.001 | -530.05 (-611.74 to -448.36) | < 0.001 | -578.08 (-704.77 to -451.39) | < 0.001 | -583.44 (-720.16 to -446.73) | < 0.001 |
IIQ-7 | |||||||||
EPNS | 7.45 (5.27) | 0.00 (Reference) | 0.00 (Reference) | 0.00 (Reference) | 0.00 (Reference) | ||||
PMFT + TES | 2.99 (5.65) | -2.86 (-5.14 to -0.58) | 0.014 | -4.46 (-5.78 to -3.14) | < 0.001 | -3.09 (-5.19 to -0.99) | 0.004 | -2.48 (-4.73 to -0.23) | 0.031 |